Aerpio Reports Third Quarter 2019 Financial Results and Provides Business Update
CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the third quarter ended September 30, 2019, and provided a business update. Recent Developments As reported on October 21, 2019, the Company announced that its Board of Directors had initiated a process to explore and review a range of strategic alternativ